Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Authors: Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha H. Shah, Ronnie Shapira‐Frommer et al.
Year: 2020
MedicinePembrolizumabInternal medicineResponse Evaluation Criteria in Solid TumorsOncology